Kymera Therapeutics, Inc.
KYMR
Classifica tra le azioni
#2300
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Prezzo delle azioni
$105.36
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$8.67B
Variazione (1 giorno)
-2.57%
Variazione (1 anno)
76.10%
Paese
US
Scambia Kymera Therapeutics, Inc. (KYMR)
Categoria
Healthcare
EPS per Kymera Therapeutics, Inc. (KYMR)
EPS al June 2026 TTM: $-3.25
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kymera Therapeutics, Inc., l’EPS attuale della società (TTM) è $-3.25. Alla fine del 2023, la società aveva un EPS di $-2.52 una diminuzione rispetto a rispetto a quello del 2022, che era di $-2.87.
Storico EPS per Kymera Therapeutics, Inc. da 2018 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-3.25 | 9.06% |
| 2024 | $-2.98 | 18.25% |
| 2023 | $-2.52 | -12.20% |
| 2022 | $-2.87 | 37.32% |
| 2021 | $-2.09 | 111.11% |
| 2020 | $-0.99 | 6.45% |
| 2019 | $-0.93 | 93.75% |
| 2018 | $-0.48 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -632.92% |
US
|
|
| $-7.98 | 145.54% |
US
|
|
| $-5.29 | 62.77% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -953.54% |
NL
|
